Genomic Health, Inc. (GHDX) Position Lifted by Carillon Tower Advisers Inc.

Carillon Tower Advisers Inc. boosted its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 2.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 75,846 shares of the medical research company’s stock after purchasing an additional 1,493 shares during the period. Carillon Tower Advisers Inc. owned approximately 0.21% of Genomic Health worth $5,326,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Globeflex Capital L P purchased a new stake in Genomic Health during the 2nd quarter worth approximately $116,000. Sun Life Financial INC purchased a new stake in Genomic Health during the 2nd quarter worth approximately $122,000. Trexquant Investment LP purchased a new stake in Genomic Health during the 3rd quarter worth approximately $202,000. SG Americas Securities LLC purchased a new stake in Genomic Health during the 2nd quarter worth approximately $162,000. Finally, D.A. Davidson & CO. purchased a new stake in Genomic Health during the 3rd quarter worth approximately $234,000. 89.21% of the stock is currently owned by institutional investors.

In related news, Director Fred E. Cohen sold 8,250 shares of the stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $61.51, for a total transaction of $507,457.50. Following the sale, the director now directly owns 75,572 shares of the company’s stock, valued at $4,648,433.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bros. Advisors Lp Baker sold 250,392 shares of the stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $75.61, for a total transaction of $18,932,139.12. The disclosure for this sale can be found here. Insiders sold a total of 986,432 shares of company stock worth $75,759,467 over the last ninety days. Insiders own 45.80% of the company’s stock.

GHDX has been the topic of several research analyst reports. Zacks Investment Research raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Monday, August 6th. BidaskClub downgraded shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Canaccord Genuity reissued a “buy” rating and set a $82.00 target price (up previously from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. Cowen reissued a “hold” rating and set a $50.00 target price on shares of Genomic Health in a research report on Monday, August 6th. Finally, Raymond James initiated coverage on shares of Genomic Health in a research report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $48.33.

GHDX stock opened at $79.05 on Monday. The firm has a market capitalization of $2.86 billion, a PE ratio of 96.40 and a beta of 0.39. Genomic Health, Inc. has a 12 month low of $26.54 and a 12 month high of $92.18.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.07 by $0.28. The business had revenue of $101.30 million for the quarter, compared to the consensus estimate of $94.27 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.06) EPS. As a group, sell-side analysts predict that Genomic Health, Inc. will post 1.06 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/03/genomic-health-inc-ghdx-position-lifted-by-carillon-tower-advisers-inc.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Read More: What are earnings reports?

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply